SUPN Supernus, Inc.
Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Supernus, Inc. was formerly known as Indivior Pharmaceuticals, Inc. and changed its name Supernus, Inc. in November 2026. Supernus, Inc. was incorporated in 2014 and is headquartered in Rockville, Maryland.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Supernus (NASDAQ: SUPN)
›
Supernus (NASDAQ: SUPN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 827 employees.
The shares were at 28.35 USD on 19 November 2026, down 50.3% over 52 weeks. Its 52-week range is 25.92 USD to 59.68 USD: the price is 52.5% below the high and 9.4% above the low.
Its market capitalisation is 5.89B USD.
Supernus reports return on equity of -3.6%, an operating margin of 46.9% and revenue up 13.4% year over year.
Its debt exceeds its cash by 196.00M USD, a debt-to-equity ratio of 0.04. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 54.14 USD is 91.0% above the current price. The next earnings report is expected on 23 February 2027.